Friday, October 2, 2026

Rivian Abandons 2027 Profitability Target to Fund Autonomous Vehicle Development

Rivian no longer expects to achieve profitability by 2027 due to substantial spending on autonomous vehicle technology. The decision follows an Uber-Rivian robotaxi partnership announcement and Uber's investment in the EV manufacturer, highlighting the capital-intensive nature of autonomous vehicle development.

LM Salvado
LM Salvado

March 24, 2026

Rivian Abandons 2027 Profitability Target to Fund Autonomous Vehicle Development
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Rivian Automotive has withdrawn its 2027 profitability target, citing heavy investment in autonomous vehicle development as the primary factor. The EV manufacturer is allocating significant capital to autonomous technology infrastructure instead of near-term financial targets.

The timing coincides with a robotaxi partnership between Rivian and Uber Technologies. Uber has made a strategic investment in Rivian, marking a shift in the ride-hailing company's autonomous vehicle strategy after selling its Uber ATG autonomous vehicle unit in 2020.

The 2020 sale of Uber's internal autonomous division demonstrated the substantial capital requirements of developing self-driving technology in-house. Rivian's decision to delay profitability suggests similar financial pressures as EV manufacturers balance short-term earnings against long-term positioning in AI-enabled mobility.

Rivian's partnership with Uber provides a potential deployment path for its autonomous technology through Uber's existing ride-hailing network. The R2 vehicle platform, developed by Rivian, may serve as a foundation for the robotaxi collaboration.

The profitability timeline revision reflects a broader strategic choice facing EV manufacturers: pursue immediate financial returns or invest heavily in autonomous capabilities that could determine competitive positioning in future mobility markets. Rivian has opted for the latter, prioritizing AI and autonomous infrastructure over 2027 earnings targets.

Note: This article was generated from analytical data. Proper source citations cannot be included without access to original source documents.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com